

February 11, 2025

Press release

ImaginAb Enters Agreement to Support Investigator-Initiated Trial at Memorial Sloan Kettering Cancer Center

Los Angeles, California, USA, February 11, 2025 – ImaginAb Inc., a global biotechnology company developing advanced imaging radiopharmaceuticals, today announced a new collaboration to support an investigator-initiated trial at Memorial Sloan Kettering Cancer Center (MSK). The study, led by principal investigator Dr. Adam Schoenfeld, is titled, *"Assessment of Patients' Immune Response After Treatment with Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging."*

This groundbreaking trial aims to leverage ImaginAb's proprietary lead investigational imaging agent, ⁸⁹Zr crefmirlimab berdoxam (CD8 ImmunoPET™) to assess immune responses in vivo in patients undergoing engineered tumor-infiltrating lymphocyte (TIL) therapy.

Dr. Adam Schoenfeld, a renowned expert in immuno-oncology, will oversee the trial at MSK, one of the world's leading cancer treatment and research institutions. The study highlights the growing role of CD8 ImmunoPET imaging as a valuable tool in advancing immunotherapy research and clinical care.

ImaginAb is excited to support this intriguing investigator-initiated trial at Memorial Sloan Kettering Cancer Center. "We are thankful for the opportunity to explore the ability of CD8 ImmunoPET to visualize the dynamics of whole-body CD8+ cell distribution within the context of engineered TIL therapy and TIL restimulation" said Kristin Schmiedehausen, MD, VP, Medical Affairs. "By integrating CD8 ImmunoPET imaging into this investigation, we aim to provide researchers like Dr. Schoenfeld with tools to better understand the mechanism of action of new therapeutic approaches, to facilitate the development of potential new breakthrough technologies in cancer treatment and, to contribute to the ultimate goal of improving patients' outcomes".

ENDS

About ImaginAb

A clinical stage, revenue-generating global biotechnology company developing next-generation imaging agents through its proprietary minibody and cys-diabody platforms. The lead candidate, CD8 ImmunoPET™, is currently in Phase II clinical trials and has been licensed by pharmaceutical and biotech companies for use in immunotherapy clinical trials.

About CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam)

An 89Zr-labeled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging. This method is currently being researched to determine whether it may be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies, and to predict patient outcomes.

For further information please contact:**ImaginAb**

Clinique Burrell

Corporate Communications & Administrative Manager

Email: cburrell@imaginab.com

Website: www.imaginab.com

Phone: +1 310 645 1211